

Amit J Sabnis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3382721/amit-j-sabnis-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

1,176
citations

11
h-index

18
g-index

18
ext. papers

1,425
ext. citations

15
avg, IF

3.97
L-index

#	Paper	IF	Citations
15	Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. <i>Journal of Pediatric Hematology/Oncology</i> , 2020 , 42, e647-e654	1.2	1
14	Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. <i>Trends in Molecular Medicine</i> , 2019 , 25, 185-197	11.5	53
13	EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. <i>Human Pathology</i> , 2018 , 81, 281-290	3.7	16
12	Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. <i>Journal of Cell Science</i> , 2018 , 131,	5.3	13
11	Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. <i>Science</i> , 2018 , 361,	33.3	86
10	Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 9015-20	11.5	21
9	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015 , 21, 1038-47	50.5	177
8	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015 , 47, 250-6	36.3	320
7	Neurologic Emergencies. <i>Pediatric Oncology</i> , 2015 , 71-96	0.5	
6	Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. <i>Human Mutation</i> , 2014 , 35, 318-28	4.7	16
5	FGFR fusions in the driver's seat. <i>Cancer Discovery</i> , 2013 , 3, 607-9	24.4	6
4	Oncogenic Kras initiates leukemia in hematopoietic stem cells. <i>PLoS Biology</i> , 2009 , 7, e59	9.7	77
3	JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. <i>Cancer Cell</i> , 2009 , 15, 341-52	24.3	101
2	Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. <i>Nature Genetics</i> , 2008 , 40, 963-70	36.3	285
1	Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells.. <i>Blood</i> , 2007 , 110, 778-778	2.2	